|
1
|
Abbott M and Ustoyev Y: Cancer and the
immune system: The history and background of immunotherapy. Semin
Oncol Nurs. 35:1509232019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Knaus HA, Kanakry CG, Luznik L and Gojo I:
Immunomodulatory drugs: Immune checkpoint agents in acute leukemia.
Curr Drug Targets. 18:315–331. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xie W, Hu N and Cao L: Immune
thrombocytopenia induced by immune checkpoint inhibitrs in lung
cancer: Case report and literature review. Front Immunol.
12:7900512021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang L, Mai W, Jiang W and Geng Q:
Sintilimab: A promising anti-tumor PD-1 antibody. Front Oncol.
10:5945582020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang L, Qian Y, Li J, Cui C, Chen L, Qu S
and Lu S: Indirect comparison of sintilimab and other PD-L1
inhibitors for first-line treatment of non-squamous non-small-cell
lung cancer. Future Oncol. 18:1896–1905. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ru CH and Zhuang YB: Efficacy and safety
of addition of anti-PD1 to chemotherapy in treatment of non-small
cell lung cancer. Comb Chem High Throughput Screen. 21:711–717.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jöhrens K and Rüschoff J: The challenge to
the pathologist of PD-L1 expression in tumor cells of
non-small-cell lung cancer-an overview. Curr Oncol. 28:5227–5239.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hendriks LE, Kerr KM, Menis J, Mok TS,
Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, et
al: Electronic address: simpleclinicalguidelines@esmo.org.
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO
clinical practice guideline for diagnosis, treatment and follow-up.
Ann Oncol. 34:358–376. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Simpson G and Judge DJ: Management of
malignant pleural effusion. Respirology. 20:1692015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferreiro L, Suárez-Antelo J,
Álvarez-Dobaño JM, Toubes ME, Riveiro V and Valdés L: Malignant
pleural effusion: Diagnosis and management. Can Respir J.
2020:29507512020.PubMed/NCBI
|
|
13
|
Sun Y, Hu Y, Wan C, Lovell JF, Jin H and
Yang K: Local biomaterial-assisted antitumour immunotherapy for
effusions in the pleural and peritoneal cavities caused by
malignancies. Biomater Sci. 9:6381–6390. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ruffell B, Affara NI and Coussens LM:
Differential macrophage programming in the tumor micro environment.
Trends Immunol. 33:119–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De Cicco P, Ercolano G and Ianaro A: The
new era of cancer immunotherapy: targeting myeloid-derived
suppressor cells to overcome immune evasion. Front Immunol.
11:16802020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li L, Yang L, Wang L, Wang F, Zhang Z, Li
J, Yue D, Chen X, Ping Y, Huang L, et al: Impaired T cell function
in malignant pleural effusion is caused by TGF-β derived
predominantly from macrophages. Int J Cancer. 139:2261–2269. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ba M, Long H, Wang Y, Tang Y, Wu Y, Zhang
X and Cui S: Intrapleural hyperthermic perfusion using distilled
water at 48°C for malignant pleural effusion. J Cancer Res Clin
Oncol. 139:2005–2012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shigemura N, Akashi A, Ohta M and Matsuda
H: Combined surgery of intrapleural perfusion hyperthermic
chemotherapy and panpleuropneumonectomy for lung cancer with
advanced pleural spread: a pilot study. Interact Cardiovasc Thorac
Surg. 2:671–675. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chakravarty D, Gao J, Phillips SM, Kundra
R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, et
al: OncoKB: A precision oncology knowledge base. JCO Precis Oncol.
2017.PO.17.00011. 2017. View Article : Google Scholar
|
|
20
|
Błach J, Wojas-Krawczyk K, Nicoś M and
Krawczyk P: Failure of immunotherapy-the molecular and
immunological origin of immunotherapy resistance in lung cancer.
Int J Mol Sci. 22:90302021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu W, Zheng YL, Tian LP, Lai JB, Hu CC,
Zhang P, Chen JK, Hu JB, Huang ML, Wei N, et al: Circulating T
lymphocyte subsets, cytokines, and immune checkpoint inhibitors in
patients with bipolar II or major depression: A preliminary study.
Sci Rep. 7:405302017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dolina JS, Van Braeckel-Budimir N, Thomas
GD and Salek-Ardakani S: CD8+ T cell exhaustion in cancer. Front
Immunol. 12:7152342021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang F, Yang L, Gao Q, Huang L, Wang L,
Wang J, Wang S, Zhang B and Zhang Y: CD163+CD14+ macrophages, a
potential immune biomarker for malignant pleural effusion. Cancer
Immunol Immunother. 64:965–976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang L, Wang F, Wang L, Huang L, Wang J,
Zhang B and Zhang Y: CD163+ tumor-associated macrophage
is a prognostic biomarker and is associated with therapeutic effect
on malignant pleural effusion of lung cancer patients. Oncotarget.
6:10592–10603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wahl SM, Swisher J, McCartney-Francis N
and Chen W: TGF-beta: The perpetrator of immune suppression by
regulatory T cells and suicidal T cells. J Leukoc Biol. 76:15–24.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suzuki K, Funai K, Shundo Y, Asano K,
Takamochi K, Asai K, Kazui T and Miura K: Extrapleural
pneumonectomy after hyperthermo-chemotherapy for the lung cancer
patients with malignant pleural effusion. Kyobu Geka. 57:1023–1027.
2004.(In Japanese). PubMed/NCBI
|
|
27
|
Kodama K, Doi O, Higashiyama M, Yokouchi H
and Tatsuta M: Long-term results of postoperative intrathoracic
chemo-thermotherapy for lung cancer with pleural dissemination.
Cancer. 72:426–431. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matsuzaki Y, Shibata K, Yoshioka M, Inoue
M, Sekiya R, Onitsuka T, Iwamoto I and Koga Y: Intrapleural
perfusion hyperthermo-chemotherapy for malignant pleural
dissemination and effusion. Ann Thorac Surg. 59:127–131. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao Y, Zhang Q, Huang Z, Chai Z, Liu J,
Wang J, Sun Z, Zhao T, Wang G, Chen G, et al: Better effect of
intrapleural perfusion with hyperthermic chemotherapy by
video-assisted thoracoscopic surgery for malignant pleural effusion
treatment compared to normothermic chemoperfusion of the pleural
cavity. Cancer Med. 11:348–357. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Işık AF, Sanlı M, Yılmaz M, Meteroğlu F,
Dikensoy O, Sevinç A, Camcı C, Tunçözgür B and Elbeyli L:
Intrapleural hyperthermic perfusion chemotherapy in subjects with
metastatic pleural malignancies. Respir Med. 107:762–767. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu L, Jing Y, Ma S, Li F and Zhang YF:
Cytoreductive surgery combined with hyperthermic intrapleural
chemotherapy to treat thymoma or thymic carcinoma with pleural
dissemination. Onco Targets Ther. 6:517–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang X, Kong M, Jin J, Lin Y, Jia L and Ye
M: The efficacy and safety of intrapleural hyperthermic perfusion
in patients with malignant pleural effusion undergoing
video-assisted thoracic surgery: A single-arm clinical trial. J
Thorac Dis. 14:1497–1503. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li J, Yao H, Lei Y and Ye Y: Establishment
of a human intrapleural hyperthermic perfusion model and analysis
of pleural malignancy treatment depth. Respir Med. 138:144–149.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kang MQ, Cao YP and Deng F: Impact of
intrapleural hyperthermic perfusion on immunologic reaction state
of cytokines TH1/TH2 of lung carcinoma patients with malignant
pleural effusion. Ai Zheng. 27:210–213. 2008.(In Chinese).
PubMed/NCBI
|
|
35
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
36
|
Zhu Z, Ni J, Cai X, Su S, Zhuang H, Yang
Z, Chen M, Ma S, Xie C, Xu Y, et al: International consensus on
radiotherapy in metastatic non-small cell lung cancer. Transl Lung
Cancer Res. 11:1763–1795. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Grapin M, Richard C, Limagne E, Boidot R,
Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet
JD, et al: Optimized fractionated radiotherapy with anti-PD-L1 and
anti-TIGIT: A promising new combination. J Immunother Cancer.
7:1602019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang S, Zheng Y, Yu P, Yu F, Zhang Q, Lv
Y, Xie X and Gao Y: The combined treatment of CT-guided
percutaneous 125I seed implantation and chemotherapy for
non-small-cell lung cancer. J Cancer Res Clin Oncol. 137:1813–1822.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carditello A, Scisca C, David A, Littori
F, Stilo F and Allegra G: New perspectives in the treatment of
liver metastasis from colorectal cancer: Radiofrequency thermal
ablation. G Chir. 22:407–409. 2001.PubMed/NCBI
|
|
40
|
Palussière J, Catena V, Lagarde P, Cousin
S, Cabart M, Buy X and Chomy F: Primary tumors of the lung: Should
we consider thermal ablation as a valid therapeutic option? Int J
Hyperthermia. 36:46–52. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yan L, Qing B, Shuxu Y, Mingying Y and
Chuanbin M: Bionanoparticles in cancer imaging, diagnosis, and
treatment. View. 3:1–45. 2022.PubMed/NCBI
|
|
42
|
Gao Y, Shen M and Shi X: Interaction of
dendrimers with the immune system: An insight into cancer
nanotheranostics. View 2. 1–9. 2021.
|
|
43
|
Wang L, Zhang M, Pan X, Zhao M, Huang L,
Hu X, Wang X, Qiao L, Guo Q, Xu W, et al: Integrative serum
metabolic fingerprints based multi-modal platforms for lung
adenocarcinoma early detection and pulmonary nodule classification.
Adv Sci (Weinh). 9:e22037862022. View Article : Google Scholar : PubMed/NCBI
|
